Please login to the form below
SCLC
This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.
MSD withdraws Keytruda’s US indication for small cell lung cancer
The US Food and Drug Administration (FDA) granted Keytruda (pembrolizumab) an accelerated approval for the treatment of third line SCLC in June 2019. ... However, the SCLC market has been cornered by rival checkpoint inhibitors, including Roche’s
Latest news
-
New dosing option for AZ’s Imfinzi approved in the EU and UK
The new dosing regimen is consistent with Imfinzi’s approved dosing in extensive-stage small cell lung cancer (ES-SCLC). ... of 10mg/kg approval in NSCLC and the CASPIAN phase 3 trial which used a four-week fixed-dose regimen in ES-SCLC.
-
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial
The drug scored conditional approved as a monotherapy in the metastatic, second-line setting for SCLC by the US Food and Drug Administration (FDA) n June. ... We look forward to the further development of lurbinectedin in SCLC and other tumours, both as
-
BMS’ Opdivo is first immunotherapy to score phase 3 win in pre-surgery NSCLC
Although Keytruda holds much of the NSCLC market, other immunotherapies have carved out niches in other indications – in particular the less common lung cancer type, small cell lung cancer (SCLC). ... This includes Roche’s Tecentriq, which is
-
Keytruda doubles five-year survival rate in NSCLC
That includes Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) which is approved for first-line SCLC. ... SCLC accounts for around 10-15% of all cases of lung cancer and has a poor prognosis with a five-year survival rate of approximately 6% across all
-
AZ scores FDA priority review for new Imfinzi fixed-dose regimen
Merck &Co’s checkpoint inhibitor Keytruda (pembrolizumab) currently holds much of the NSCLC market, although the drug failed to show benefit in SCLC when added to chemotherapy. ... The disappointing results in SCLC marred an otherwise dominant position
More from news
Approximately 6 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. .
-
Deal Watch April 2016
Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
-
Deal Watch November 2015
July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director - Med Comms Agency
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
- Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU
- Roche, Genentech partner with The Weill Neurohub on ten-year neuroscience collaboration
- AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset
- Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition
- GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
- Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s
- CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Gene Editing and Precision Medicine: The Future of Healthcare?
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
Quick links
Infographics
